These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 29695292

  • 21. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging.
    Ottoy J, Niemantsverdriet E, Verhaeghe J, De Roeck E, Struyfs H, Somers C, Wyffels L, Ceyssens S, Van Mossevelde S, Van den Bossche T, Van Broeckhoven C, Ribbens A, Bjerke M, Stroobants S, Engelborghs S, Staelens S.
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [Abstract] [Full Text] [Related]

  • 22. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
    Selnes P, Aarsland D, Bjørnerud A, Gjerstad L, Wallin A, Hessen E, Reinvang I, Grambaite R, Auning E, Kjærvik VK, Due-Tønnessen P, Stenset V, Fladby T.
    J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
    [Abstract] [Full Text] [Related]

  • 23. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [Abstract] [Full Text] [Related]

  • 24. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
    Botha H, Mantyh WG, Murray ME, Knopman DS, Przybelski SA, Wiste HJ, Graff-Radford J, Josephs KA, Schwarz CG, Kremers WK, Boeve BF, Petersen RC, Machulda MM, Parisi JE, Dickson DW, Lowe V, Jack CR, Jones DT.
    Brain; 2018 Apr 01; 141(4):1201-1217. PubMed ID: 29538658
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer's Disease Outcomes.
    McLimans KE, Willette AA, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2017 Apr 01; 56(1):403-413. PubMed ID: 27911319
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Res Ther; 2018 Aug 16; 10(1):80. PubMed ID: 30115118
    [Abstract] [Full Text] [Related]

  • 33. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M.
    Dement Geriatr Cogn Disord; 2010 Aug 16; 30(4):285-92. PubMed ID: 20861634
    [Abstract] [Full Text] [Related]

  • 34. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
    Silva-Rodríguez J, Labrador-Espinosa MA, Moscoso A, Schöll M, Mir P, Grothe MJ, Alzheimer’s Disease Neuroimaging Initiative.
    Brain; 2023 Nov 02; 146(11):4520-4531. PubMed ID: 37284793
    [Abstract] [Full Text] [Related]

  • 35. Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.
    Pyun JM, Park YH, Kim HR, Suh J, Kang MJ, Kim BJ, Youn YC, Jang JW, Kim S, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Res Ther; 2017 Dec 16; 9(1):99. PubMed ID: 29246250
    [Abstract] [Full Text] [Related]

  • 36. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2015 Aug 16; 11(8):986-93. PubMed ID: 25916563
    [Abstract] [Full Text] [Related]

  • 37. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y, Lou F, Li Y, Liu F, Wang Y, Cai L, Gordon ML, Zhang Y, Zhang N.
    Curr Alzheimer Res; 2021 Aug 16; 18(6):523-532. PubMed ID: 34598664
    [Abstract] [Full Text] [Related]

  • 38. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.
    Liguori C, Chiaravalloti A, Nuccetelli M, Izzi F, Sancesario G, Cimini A, Bernardini S, Schillaci O, Mercuri NB, Fabio P.
    J Neurol; 2017 Nov 16; 264(11):2215-2223. PubMed ID: 28900724
    [Abstract] [Full Text] [Related]

  • 39. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 16; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.